IP Library Granted Patent US 7,303,757
Granted Patent B2
US 7,303,757 · App. 10/635,847 · Granted Dec 4, 2007

Biocompatible phase invertable proteinaceous compositions and methods for making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,303,757
App. No.
10/635,847
Granted
Dec 4, 2007
Kind
B2
Abstract

Biocompatible phase invertable proteinaceous compositions and methods for making and using the same are provided. The subject phase invertable compositions are prepared by combining a proteinaceous substrate and a cross-linker. The proteinaceous substrate includes one or more proteins and an adhesion modifier, and may also include one or more of: a pasticizer, a carbohydrate, or other modification agent. In certain embodiments, the cross-linker is a heat-treated dialdehyde, e.g., heat-treated glutaraldehyde. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.

Claims (79)

1. A fluid phase invertible composition that goes from a first fluid state to a second non-fluid state in which said composition is incapable of fluid flow, wherein said composition is produced by combining:

(a) a fluid substrate comprising a proteinaceous material, wherein said proteinaceous material comprises one or more of: albumin, elastin, fibrin and soluble and insoluble forms of collagen and combinations thereof, and

(b) a heat stabilized dialdehyde crosslinking agent that has been produced by maintaining an initial dialdehyde crosslinking composition at a temperature ranging from about 45 to about 55° C. for a period of time ranging from about 1 to about 20 days, wherein said heat stabilized crosslinking agent has been heat stabilized prior to contacting said substrate;

wherein said fluid phase invertible composition goes from a first fluid state to a second non-fluid state in which said composition is incapable of fluid flow in a period of time ranging from about 10 seconds to about 10 minutes following crosslinking-of said substrate by said heat stabilized dialdehyde crosslinking agent.

2. The phase invertible composition according to claim 1 , wherein said substrate further comprises an adhesion modifier.

3. The phase invertible composition according to claim 2 , wherein said adhesion modifier is chosen from polyethyleneimine, gelatin and carboxymethylcellulose.

4. The phase invertible composition according to claim 1 , wherein said substrate further comprises a plasticizer.

5. The phase invertible composition according to claim 3 , wherein the plasticizer is chosen from polyethylene glycol, glycerin, a fatty acid, butylhydroxytoluene, and combinations thereof.

6. The phase invertible composition according to claim 1 , wherein said substrate further comprises a carbohydrate.

7. The phase invertible composition according to claim 1 , wherein said substrate further comprises a filler.

8. The phase invertible composition according to claim 1 , wherein said substrate further comprises a polyblend.

9. The phase invertible composition according to claim 1 , wherein said substrate further comprises a biologically active agent.

10. The phase invertible composition according to claim 1 , wherein said substrate further comprises a foaming agent.

11. The phase invertible composition according to claim 1 , wherein said crosslinking agent comprises glutaraldehyde.

12. A fluid phase invertible composition that goes from a first fluid state to a second non-fluid state in which said composition is incapable of fluid flow, wherein said composition is produced by combining:

(a) a fluid substrate comprising:

(i) a proteinaceous material, wherein said proteinaceous material comprises one or more of: albumin, elastin, fibrin and soluble and insoluble forms of collagen and combinations thereof, and

(ii) an adhesion modifier; and

(b) a heat stabilized dialdehyde crosslinking agent that has been produced by maintaining an initial dialdehyde crosslinking composition at a temperature ranging from about 45 to about 55° C. for a period of time ranging from about 1 to about 20 days, wherein said heat stabilized crosslinking agent has been heat stabilized prior to contacting said substrate;

wherein said fluid phase invertible composition goes from a first fluid state to a second non-fluid state in which said composition is incapable of fluid flow in a period of time ranging from about 10 seconds to about 10 minutes following crosslinking of said substrate by said heat stabilized dialdehyde crosslinking agent.

13. A fluid phase invertible composition that goes from a first fluid state to a second non-fluid state in which said composition is incapable of fluid flow, wherein said composition is produced by combining:

(a) a fluid substrate comprising:

(i) a proteinaceous material, wherein said proteinaceous material comprises one or more of: albumin, elastin, fibrin and soluble and insoluble forms of collagen and combinations thereof;

(ii) an adhesion modifier; and

(iii) a plasticizer; and

(b) a heat stabilized dialdehyde crosslinking agent that has been produced by maintaining an initial dialdehyde crosslinking composition at a temperature ranging from about 45 to about 55° C. for a period of time ranging from about 1 to about 20 days, wherein said heat stabilized crosslinking agent has been heat stabilized prior to contacting said substrate;

wherein said fluid phase invertible composition is goes from a first fluid state to a second non-fluid state in which said composition is incapable of fluid flow in a period of time ranging from about 10 seconds to about 10 minutes following crosslinking of said substrate by said heat stabilized dialdehyde crosslinking agent.

14. A method comprising:

(i) producing a fluid phase invertible composition in a step consisting essentially of mixing:

(a) a fluid substrate comprising a proteinaceous material, wherein said proteinaceous material comprises one or more of: albumin, elastin, fibrin and soluble and insoluble forms of collagen and combinations thereof; and

(b) a heat stabilized dialdehyde crosslinking agent that has been produced by maintaining an initial dialdehyde crosslinking composition at a temperature ranging from about 45 to about 55° C. for a period of time ranging from about 1 to about 20 days;

to produce said fluid phase invertible composition that goes from a first fluid state to a second non-fluid state in which said composition is incapable of fluid flow in a period of time ranging from about 10 second to about 10 minutes following combination of said substrate and said crosslinking agent; and

(ii) delivering said phase invertible composition to a site of a subject before said composition goes from said first fluid state to said second non-fluid state so that said phase invertible composition is delivered to said site of said subject in said first fluid state.

15. The phase invertible composition according to claim 12 , wherein said substrate further comprises a plasticizer.

16. The phase invertible composition according to claim 15 , wherein the plasticizer is chosen from polyethylene glycol, glycerin, a fatty acid, butylhydroxytoluene, and combinations thereof.

17. The phase invertible composition according to claim 12 , wherein said adhesion modifier is chosen from polyethyleneimine, gelatin and carboxymethylcellulose.

18. The phase invertible composition according to claim 12 , wherein said substrate further comprises a carbohydrate.

19. The phase invertible composition according to claim 12 , wherein said substrate further comprises a filler.

20. The phase invertible composition according to claim 12 , wherein said substrate further comprises a polyblend.

21. The phase invertible composition according to claim 12 , wherein said substrate further comprises a biologically active agent.

22. The phase invertible composition according to claim 12 , wherein said substrate further comprises a foaming agent.

23. The phase invertible composition according to claim 12 , wherein said crosslinking agent comprises glutaraldehyde.

24. The phase invertible composition according to claim 13 , wherein the plasticizer is chosen from polyethylene glycol, glycerin, a fatty acid, butylhydroxytoluene, and combinations thereof.

25. The phase invertible composition according to claim 13 , wherein said adhesion modifier is chosen from polyethyleneimine, gelatin and carboxymethylcellulose.

26. The phase invertible composition according to claim 13 , wherein said substrate further comprises a carbohydrate.

27. The phase invertible composition according to claim 13 , wherein said substrate further comprises a filler.

28. The phase invertible composition according to claim 13 , wherein said substrate further comprises a polyblend.

29. The phase invertible composition according to claim 13 , wherein said substrate further comprises a biologically active agent.

30. The phase invertible composition according to claim 13 , wherein said substrate further comprises a foaming agent.

31. The phase invertible composition according to claim 13 , wherein said crosslinking agent comprises glutaraldehyde.

32. The method according to claim 14 , wherein said substrate further comprises an adhesion modifier.

33. The method according to claim 32 , wherein said adhesion modifier is chosen from polyethyleneimine, gelatin and carboxymethylcellulose.

34. The method according to claim 14 , wherein said substrate further comprises a plasticizer.

35. The method according to claim 34 , wherein the plasticizer is chosen from polyethylene glycol, glycerin, a fatty acid, butylhydroxytoluene, and combinations thereof.

36. The method according to claim 14 , wherein said substrate further comprises a carbohydrate.

37. The method according to claim 14 , wherein said substrate further comprises a filler.

38. The method according to claim 14 , wherein said substrate further comprises a polyblend.

39. The method according to claim 14 , wherein said substrate further comprises a biologically active agent.

40. The method according to claim 14 , wherein said substrate further comprises a foaming agent.

41. The method according to claim 14 , wherein said crosslinking agent comprises glutaraldehyde.

42. A solid phase composition produced by the method of claim 14 .

43. A kit for producing a fluid phase invertible composition, said kit consisting essentially of:

(a) a fluid substrate comprising a proteinaceous material, wherein said proteinaceous material comprises one or more of: albumin, elastin, fibrin and soluble and insoluble forms of collagen and combinations thereof;

(b) a heat stabilized dialdehyde crosslinking agent that has been produced by maintaining an initial dialdehyde crosslinking composition at a temperature ranging from about 45 to about 55° C. for a period of time ranging from about 1 to about 20 days; and

(c) a mixing element for thoroughly combining said substrate and said crosslinker with each other to produce said fluid phase invertible composition;

wherein said components (a) and (b) are present in separate containers in said kit.

44. The kit according to claim 43 , wherein said kit further comprises a fluid delivery device.

45. The kit according to claim 43 , wherein said fluid delivery device is a catheter.

46. The kit according to claim 43 , wherein said kit further comprises a guiding element.

47. The method according to claim 14 , wherein said site is a vascular site.

48. The method according to claim 47 , wherein said method comprises producing a structural member from said phase invertible composition at said vascular site.

49. The method according to claim 48 , wherein said structural member is a stent.

50. The method according to claim 49 , wherein said method comprises delivering said phase invertible composition using a fluid delivery device.

51. The method according to claim 50 , wherein said fluid delivery device is a catheter having first and second occlusion members and an expandable mandrel at its distal end.

52. The method according to claim 51 , wherein said method comprises:.

occluding said first and second occlusion members and expanding said mandrel to produce a mold space; and

delivering said phase invertible composition to said mold space when said composition is in said first fluid state.

53. The composition according to claim 1 , wherein said heat stabilized dialdehyde crosslinking agent is produced by maintaining a dialdehyde composition at a at a temperature of from about 35 to about 60° C. for a period of time ranging from about 1 to about 20 days.

54. The composition according to claim 53 , wherein said dialdehyde is a glutaraldehyde.

Assignments (6)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043596, FRAME 0259 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2018
From: MATRIX MEDICAL LLC
To: TENAXIS MEDICAL, INC.
Reel/Frame 045840/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2018
From: MALLINCKRODT PHARMA IP TRADING DAC
To: BAXTER INTERNATIONAL, INC.
Reel/Frame 045754/0904 →
NUNC PRO TUNC ASSIGNMENT Recorded Oct 3, 2017
From: TENAXIS MEDICAL, INC.
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 043767/0923 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043596/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2004
From: SCHANKERELI, KEMAL; DIECK, RONALD
To: MATRIX MEDICAL, LLC
Reel/Frame 014246/0133 →